Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2024-01-09 00:00:00 ET · period of report 2024-01-06 · accession 0001209191-24-001269 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-09 | 2024-01-08 | ACAD | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $29.96 | -3,732 | 96.5K | -4% | -$111.8K |
| D | 2024-01-09 | 2024-01-06 | ACAD | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +9,528 | 100.3K | +11% | — |
| D | 2024-01-09 | 2024-01-06 | ACAD | DAVIS STEPHEN | CEO, Dir | M - OptEx | $0.00 | -9,528 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-08 | S | D | 3,732 | $29.96 | 96,521 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.63 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| 2 | Common | Common Stock | 2024-01-06 | M | A | 9,528 | — | 100,253 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. (F2) Includes 1,594 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on May 15, 2023. On October 6, 2023, the Reporting Person filed a Form 4 which reported the same acquisition of shares in a footnote to Table I, Column 5, but inadvertently omitted such shares from the total in Table I, Column 5. The May 15, 2023 acquisition by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan is now correctly included in Table I, Column 5 of this Form 4. |
| 3 | Derivative | Restricted Stock Units | 2024-01-06 | M | D | 9,528 | $0.00 | 0 | D | — · — to — | 9,528 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. (F5) The restricted stock units vest in four equal annual installments beginning January 6, 2021. |